Zepbound 15 MG/0.5 ML pen 0.5ML
Ended Awarded Last action
- Contract number
- SPE2DR26FN1Y4
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $57,862
Award facts
- Contract value 100% obligated
- $57,862.08 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $57.86K firm fixed-price delivery order to Amerisourcebergen Drug Corp (parent company Cencora, Inc.) on February 4, 2026, for Zepbound 15 mg/0.5 mL pen injectors, with an ultimate completion date of February 5, 2026. The contract was competitively awarded with no set-aside designation and will be performed at the awardee's facility in Conshohocken, Pennsylvania. This delivery order represents a single task order under Amerisourcebergen's larger indefinite delivery contract with DLA Troop Support Medical, a $999.99M prime vendor agreement (SPE2DX) that runs through December 2026 and serves as the primary vehicle for supplying a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs worldwide.
Zepbound is a semaglutide-based weight management medication indicated for chronic weight management in adults with obesity or overweight conditions with weight-related comorbidities. As a major pharmaceutical distributor, Amerisourcebergen has demonstrated significant capability in fulfilling federal medical procurement requirements across multiple therapeutic domains, including specialty medications, brand-name and generic drugs, and medical devices. The company's extensive portfolio of federal contracts with DLA reflects its critical role in ensuring reliable pharmaceutical supply chains for military treatment facilities, the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems.
Quick answers
Who was awarded contract SPE2DR26FN1Y4?
SPE2DR26FN1Y4 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on February 4, 2026.
How much is contract SPE2DR26FN1Y4 worth?
The government has obligated $57,862 on SPE2DR26FN1Y4.
Is contract SPE2DR26FN1Y4 an order under another contract?
Yes. SPE2DR26FN1Y4 is a delivery order under SPE2DR25D2211, an indefinite delivery contract.
Was contract SPE2DR26FN1Y4 competed?
The extent of competition for SPE2DR26FN1Y4 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award